Edwards Lifesciences Co. (NYSE:EW) Shares Sold by Sector Gamma AS

Sector Gamma AS decreased its position in shares of Edwards Lifesciences Co. (NYSE:EW) by 6.7% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 99,000 shares of the medical research company’s stock after selling 7,153 shares during the period. Edwards Lifesciences accounts for approximately 2.5% of Sector Gamma AS’s portfolio, making the stock its 17th biggest holding. Sector Gamma AS’s holdings in Edwards Lifesciences were worth $7,329,000 at the end of the most recent quarter.

Several other institutional investors also recently added to or reduced their stakes in the company. Abacus Planning Group Inc. increased its position in Edwards Lifesciences by 0.3% during the fourth quarter. Abacus Planning Group Inc. now owns 40,207 shares of the medical research company’s stock worth $2,977,000 after buying an additional 140 shares during the period. Bowman & Co S.C. grew its stake in shares of Edwards Lifesciences by 1.2% in the 4th quarter. Bowman & Co S.C. now owns 12,487 shares of the medical research company’s stock valued at $924,000 after purchasing an additional 148 shares during the last quarter. Moors & Cabot Inc. grew its stake in shares of Edwards Lifesciences by 0.3% in the 4th quarter. Moors & Cabot Inc. now owns 54,589 shares of the medical research company’s stock valued at $4,041,000 after purchasing an additional 152 shares during the last quarter. Pegasus Asset Management Inc. grew its stake in shares of Edwards Lifesciences by 0.4% in the 4th quarter. Pegasus Asset Management Inc. now owns 42,628 shares of the medical research company’s stock valued at $3,156,000 after purchasing an additional 159 shares during the last quarter. Finally, Mount Yale Investment Advisors LLC boosted its stake in shares of Edwards Lifesciences by 1.9% in the fourth quarter. Mount Yale Investment Advisors LLC now owns 8,563 shares of the medical research company’s stock valued at $634,000 after buying an additional 162 shares in the last quarter. Institutional investors and hedge funds own 79.46% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on EW shares. Wolfe Research downgraded Edwards Lifesciences from a “hold” rating to a “strong sell” rating in a research note on Wednesday, February 12th. Barclays lifted their price target on Edwards Lifesciences from $88.00 to $90.00 and gave the company an “overweight” rating in a research note on Thursday, February 13th. Piper Sandler lifted their price target on Edwards Lifesciences from $70.00 to $73.00 and gave the company a “neutral” rating in a research note on Wednesday, February 12th. Evercore ISI decreased their price target on Edwards Lifesciences from $75.00 to $73.00 and set an “in-line” rating on the stock in a research note on Wednesday, February 12th. Finally, Canaccord Genuity Group lifted their price target on Edwards Lifesciences from $68.00 to $71.00 and gave the company a “hold” rating in a research note on Thursday, February 13th. One equities research analyst has rated the stock with a sell rating, fourteen have given a hold rating and twelve have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $79.95.

Edwards Lifesciences Stock Performance

NYSE EW opened at $70.91 on Friday. The stock has a market cap of $41.69 billion, a price-to-earnings ratio of 10.17, a price-to-earnings-growth ratio of 4.82 and a beta of 1.12. The business has a fifty day moving average of $71.48 and a 200-day moving average of $70.35. Edwards Lifesciences Co. has a fifty-two week low of $58.93 and a fifty-two week high of $96.12. The company has a quick ratio of 2.89, a current ratio of 3.46 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW) last released its earnings results on Tuesday, February 11th. The medical research company reported $0.59 earnings per share for the quarter, topping the consensus estimate of $0.55 by $0.04. Edwards Lifesciences had a return on equity of 19.40% and a net margin of 72.93%. As a group, analysts predict that Edwards Lifesciences Co. will post 2.45 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Edwards Lifesciences news, CEO Bernard J. Zovighian sold 6,164 shares of the firm’s stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $69.51, for a total transaction of $428,459.64. Following the completion of the sale, the chief executive officer now owns 59,083 shares in the company, valued at $4,106,859.33. This trade represents a 9.45 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Steven R. Loranger sold 5,739 shares of the firm’s stock in a transaction that occurred on Friday, February 14th. The shares were sold at an average price of $76.42, for a total value of $438,574.38. Following the sale, the director now owns 60,372 shares of the company’s stock, valued at approximately $4,613,628.24. This trade represents a 8.68 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 51,303 shares of company stock worth $3,715,776. 1.29% of the stock is owned by company insiders.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.